Targeting Type II and Clara Cells for Adenovirus-mediated Gene Transfer Using the Surfactant Protein B Promoter

Strayer, Marlene S.; Guttentag, Susan H.; Ballard, Philip L.

doi:10.1165/ajrcmb.18.1.2878

Cited by 38 publications

(17 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Surfactant protein B (SP-B) expression is also limited to lung cells (20)(21)(22)(23). Strayer et al (24) showed that an adenoviral vector that expresses the lacZ gene driven by the 5' flanking region of the SP-B promoter (rAd.SPB.lacZ) targeted H441 and A549 adenocarcinoma cells but not HeLa cervical cancer cells and primary human fetal lung fibroblasts. In contrast, an adenoviral vector that expresses the lacZ gene driven by the constitutive RSV promoter (rAd.RSV.lacZ) targeted all the cells tested.…”

Section: Tissue-specific Promoter Systemsmentioning

confidence: 99%

Adenovirus-mediated cancer gene therapy and virotherapy (Review)

Fukazawa¹

2009

Int J Mol Med

View full text Add to dashboard Cite

Abstract. Gene therapy and virotherapy are among the approaches currently used to treat malignant tumors. Gene therapy and virotherapy use a specific therapeutic gene that causes death in cancer cells. In early attempts at gene therapy, therapeutic genes were driven by ubiquitous promoters such as the CMV promoter, which induce non-specific toxicity to normal cells and tissues in addition to the cancer cells. Recently, novel cancer-and/or tissue-specific promoter systems have been developed to target cancer cells but not normal cells including stem cells. In this review, we describe cancer and/or tissue-specific gene therapy systems for the treatment of cancer. In particular, we will discuss three systems for gene therapy and virotherapy: i) tissue-specific promoter systems, ii) cancer-specific promoter systems, and iii) oncolytic virotherapy. We will also discuss the major challenges of cancer-targeting vector systems and future directions in this area.

show abstract

Section: Tissue-specific Promoter Systemsmentioning

confidence: 99%

Adenovirus-mediated cancer gene therapy and virotherapy (Review)

Fukazawa¹

2009

Int J Mol Med

View full text Add to dashboard Cite

show abstract

“…In part, this situation reflects the importance of SP-B protein in surfactant physiology (Curstedt et al, 1987;Nogee et al, 1993). However, analysis of SP-B transcription has been greatly facilitated by the use of a human Clara cell tumor line, H441, which expresses SP-B (Bohinski et al, 1994;Bingle, 1997;Strayer et al, 1998). These studies have shed considerable light on the activation of SP-B transcription.…”

Section: Discussionmentioning

confidence: 99%

Activation of surfactant protein-B transcription: Signaling through the SP-A receptor utilizing the PI3 kinase pathway

Strayer

Korutla

2000

J. Cell. Physiol.

View full text Add to dashboard Cite

This study describes receptor-activated signaling initiated by surfactant protein-A (SP-A), and the means by which it activates transcription of surfactant protein-B. Pulmonary surfactant is a mixture of lipids and associated proteins produced by type II pneumocytes. Interaction of SP-A with its cognate receptor (SPAR) on type II cells is involved in regulating surfactant secretion. This interaction also increases transcription of surfactant proteins and several other genes. To study SP-A cytokine activity, we used as a model surfactant-protein (SP-B) transcription, the activators of which have been characterized. HNF-3 and TTF-1 transcription factors are known to stimulate SP-B transcription. SP-A caused increased phosphorylation and nuclear localization of both. Corresponding increases in protein binding to the SP-B promoter were demonstrated by gel shift analysis. SP-A increased protein binding to HNF-3 and TTF-1 consensus recognition elements. Footprinting analysis indicated that SP-A-induced protein binding to SP-B promoter was greater in amount, but not different in location, from that seen in control cells, which normally transcribe SP-B. SP-A caused transient increases in PI3 kinase localization at the plasma membrane, and SP-A signaling to elicit increased SP-B transcription was blocked by LY294002, an inhibitor of PI3 kinase. Therefore, SP-A signals through PI3 kinase to increase SP-B transcription in type II pneumocytes by enhancing TTF-1 and HNF-3 activation of the SP-B promoter. SP-A activation of this signaling pathway, which affects many cellular functions and has not previously been implicated in type II cell transcriptional activity, has profound import for understanding type II cell biology.

show abstract

“…Gene therapy has been widely investigated in cell-selective targeting. 184 Alveolar macrophages are an attractive vehicle by which to deliver a chemotherapeutic agent to the lymph nodes through the lymphatic circulation. Liposomes and microspheres are generally engulfed by alveolar macrophages.…”

Section: Cell Targetingmentioning

confidence: 99%

Inhaled chemotherapy in lung cancer: future concept of nanomedicine

Zarogoulidis

Chatzaki²,

Porpodis³

et al. 2012

IJN

166

160

View full text Add to dashboard Cite

Regional chemotherapy was first used for lung cancer 30 years ago. Since then, new methods of drug delivery and pharmaceuticals have been investigated in vitro, and in animals and humans. An extensive review of drug delivery systems, pharmaceuticals, patient monitoring, methods of enhancing inhaled drug deposition, safety and efficacy, and also additional applications of inhaled chemotherapy and its advantages and disadvantages are presented. Regional chemotherapy to the lung parenchyma for lung cancer is feasible and efficient. Safety depends on the chemotherapy agent delivered to the lungs and is dose-dependent and time-dependent. Further evaluation is needed to provide data regarding early lung cancer stages, and whether regional chemotherapy can be used as neoadjuvant or adjuvant treatment. Finally, inhaled chemotherapy could one day be administered at home with fewer systemic adverse effects.

show abstract

Targeting Type II and Clara Cells for Adenovirus-mediated Gene Transfer Using the Surfactant Protein B Promoter

Cited by 38 publications

References 51 publications

Adenovirus-mediated cancer gene therapy and virotherapy (Review)

Adenovirus-mediated cancer gene therapy and virotherapy (Review)

Activation of surfactant protein-B transcription: Signaling through the SP-A receptor utilizing the PI3 kinase pathway

Inhaled chemotherapy in lung cancer: future concept of nanomedicine

Contact Info

Product

Resources

About